BMS-754807
BMS-754807 is an investigational small molecule inhibitor that targets the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR). It is being studied for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit | edit source]
BMS-754807 functions by inhibiting the activity of IGF-1R and IR, which are both involved in the signaling pathways that regulate cell growth, survival, and proliferation. The IGF-1R is a receptor tyrosine kinase that, when activated, can lead to the activation of the PI3K/AKT/mTOR pathway and the Ras/Raf/MEK/ERK pathway, both of which are critical for cancer cell survival and proliferation. By inhibiting these receptors, BMS-754807 aims to disrupt these pathways, thereby inhibiting tumor growth and inducing apoptosis in cancer cells.
Preclinical Studies[edit | edit source]
In preclinical studies, BMS-754807 has demonstrated potent antitumor activity in various cancer cell lines, including those of breast cancer, prostate cancer, and lung cancer. These studies have shown that BMS-754807 can effectively inhibit cell proliferation and induce apoptosis in cancer cells that overexpress IGF-1R and IR.
Clinical Development[edit | edit source]
BMS-754807 has been evaluated in early-phase clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors. These trials have provided insights into the pharmacokinetics and pharmacodynamics of the drug, as well as its potential therapeutic benefits and side effects.
Potential Side Effects[edit | edit source]
As with many investigational cancer therapies, BMS-754807 may cause a range of side effects. Commonly reported adverse effects include nausea, fatigue, and hyperglycemia, which are consistent with the inhibition of the insulin receptor.
Research and Future Directions[edit | edit source]
Ongoing research is focused on identifying biomarkers that predict response to BMS-754807, as well as exploring combination therapies that may enhance its efficacy. The drug is also being studied in combination with other targeted therapies and chemotherapy agents to determine synergistic effects.
Also see[edit | edit source]
- Insulin-like growth factor 1 receptor
- Insulin receptor
- Cancer therapy
- Tyrosine kinase inhibitors
- Apoptosis
Template:Receptor tyrosine kinase inhibitors
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
